ZA200508722B - Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 - Google Patents
Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 Download PDFInfo
- Publication number
- ZA200508722B ZA200508722B ZA200508722A ZA200508722A ZA200508722B ZA 200508722 B ZA200508722 B ZA 200508722B ZA 200508722 A ZA200508722 A ZA 200508722A ZA 200508722 A ZA200508722 A ZA 200508722A ZA 200508722 B ZA200508722 B ZA 200508722B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzyl
- amino
- acetic acid
- dimethylamino
- chloro
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 102000009389 Prostaglandin D receptors Human genes 0.000 title claims description 18
- 108050000258 Prostaglandin D receptors Proteins 0.000 title claims description 18
- 201000010099 disease Diseases 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 11
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title description 3
- 230000001404 mediated effect Effects 0.000 title description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 167
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 68
- -1 nitro, guanidino, pyrrolyl Chemical group 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 150000002148 esters Chemical class 0.000 claims description 25
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 5
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 201000009890 sinusitis Diseases 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims description 4
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 4
- 206010052568 Urticaria chronic Diseases 0.000 claims description 4
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 4
- 208000024376 chronic urticaria Diseases 0.000 claims description 4
- 206010024378 leukocytosis Diseases 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
- ZNTGLJGJOQBPOJ-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(2-cyclohexylacetyl)amino]phenyl]methyl]-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)CC3CCCCC3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 ZNTGLJGJOQBPOJ-UHFFFAOYSA-N 0.000 claims description 2
- CUNNBJJEJUDKNN-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 CUNNBJJEJUDKNN-UHFFFAOYSA-N 0.000 claims description 2
- OVWALNLURHWQRX-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(quinoline-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3N=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 OVWALNLURHWQRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- NRRCYZPJUABYHL-UHFFFAOYSA-N 2-Pyrimidine Acetic Acid Chemical class OC(=O)CC1=NC=CC=N1 NRRCYZPJUABYHL-UHFFFAOYSA-N 0.000 claims 3
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- QLEXLARZQWPJAH-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(4-fluorophenyl)methoxycarbonylamino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)OCC=3C=CC(F)=CC=3)=CC=2)=N1 QLEXLARZQWPJAH-UHFFFAOYSA-N 0.000 claims 2
- UUEHKVXKFVUOKF-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-(phenylmethoxycarbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)OCC=3C=CC=CC=3)=CC=2)=N1 UUEHKVXKFVUOKF-UHFFFAOYSA-N 0.000 claims 2
- 125000002999 4-(trifluoromethyl)benzoyl group Chemical group FC(C1=CC=C(C(=O)*)C=C1)(F)F 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- BRAVLCWGFGRYAJ-UHFFFAOYSA-N 2-[2-[(4-benzamidophenyl)methyl]-4-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=CC=CC=3)=CC=2)=NC=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 BRAVLCWGFGRYAJ-UHFFFAOYSA-N 0.000 claims 1
- VNJYZANVNXLMBK-UHFFFAOYSA-N 2-[2-[1-[4-[(3,4-dichlorobenzoyl)amino]phenyl]ethyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound N=1C=C(CC(O)=O)C(N(C)C)=NC=1C(C)C(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 VNJYZANVNXLMBK-UHFFFAOYSA-N 0.000 claims 1
- WFSKXLWLRRRIJO-UHFFFAOYSA-N 2-[2-[1-[4-[(4-chlorobenzoyl)amino]phenyl]ethyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound N=1C=C(CC(O)=O)C(N(C)C)=NC=1C(C)C(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 WFSKXLWLRRRIJO-UHFFFAOYSA-N 0.000 claims 1
- AOUSMRYWAUOLEC-UHFFFAOYSA-N 2-[2-[[3-[(2-cyclopropylacetyl)amino]phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=CN=C1CC(C=1)=CC=CC=1NC(=O)CC1CC1 AOUSMRYWAUOLEC-UHFFFAOYSA-N 0.000 claims 1
- YSUZNPRBTKHJCF-UHFFFAOYSA-N 2-[2-[[3-[[2-(1,3-benzodioxol-5-yl)acetyl]amino]phenyl]methyl]-4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=C(NC(=O)CC=3C=C4OCOC4=CC=3)C=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 YSUZNPRBTKHJCF-UHFFFAOYSA-N 0.000 claims 1
- AVTWECVCWPNYJR-UHFFFAOYSA-N 2-[2-[[3-[[benzyl(methyl)carbamoyl]amino]phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=C(NC(=O)N(C)CC=3C=CC=CC=3)C=CC=2)=N1 AVTWECVCWPNYJR-UHFFFAOYSA-N 0.000 claims 1
- OQGHYGCQIHVPKX-UHFFFAOYSA-N 2-[2-[[4-(3,3-dimethylbutanoylamino)phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=CC(NC(=O)CC(C)(C)C)=CC=C1CC1=NC=C(CC(O)=O)C(N2CCCC2)=N1 OQGHYGCQIHVPKX-UHFFFAOYSA-N 0.000 claims 1
- QWKZLHMASPOSDC-UHFFFAOYSA-N 2-[2-[[4-(benzylcarbamoylamino)phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)NCC=3C=CC=CC=3)=CC=2)=N1 QWKZLHMASPOSDC-UHFFFAOYSA-N 0.000 claims 1
- VIACNMLRKMDHEV-UHFFFAOYSA-N 2-[2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC1=CN=C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)N=C1N1CCCC1 VIACNMLRKMDHEV-UHFFFAOYSA-N 0.000 claims 1
- BLGFEKQGRRINTG-UHFFFAOYSA-N 2-[2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-4,6-bis(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)=CC=2)=N1 BLGFEKQGRRINTG-UHFFFAOYSA-N 0.000 claims 1
- ZLEDKTARFAGUKH-UHFFFAOYSA-N 2-[2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-4-(dimethylamino)-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 ZLEDKTARFAGUKH-UHFFFAOYSA-N 0.000 claims 1
- WULJEVKZTZYJFW-UHFFFAOYSA-N 2-[2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)=CC=2)=N1 WULJEVKZTZYJFW-UHFFFAOYSA-N 0.000 claims 1
- OXZAIUCHPIZYDI-UHFFFAOYSA-N 2-[2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-4-methyl-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(C)=NC=1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 OXZAIUCHPIZYDI-UHFFFAOYSA-N 0.000 claims 1
- QBCSHZVZVUKCQO-UHFFFAOYSA-N 2-[2-[[4-[(4-acetamidobenzoyl)amino]phenyl]methyl]-4-chloro-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N2CCCC2)=N1 QBCSHZVZVUKCQO-UHFFFAOYSA-N 0.000 claims 1
- AARBEQQNTOZBTL-UHFFFAOYSA-N 2-[2-[[4-[(4-bromobenzoyl)amino]phenyl]methyl]-4-chloro-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=CC(Br)=CC=3)=CC=2)=N1 AARBEQQNTOZBTL-UHFFFAOYSA-N 0.000 claims 1
- NGQGKGLUXQOOTE-UHFFFAOYSA-N 2-[2-[[4-[(4-chlorobenzoyl)amino]phenyl]methyl]-4-(dimethylamino)-6-morpholin-4-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCOCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 NGQGKGLUXQOOTE-UHFFFAOYSA-N 0.000 claims 1
- LACBHKONDFDLLO-UHFFFAOYSA-N 2-[2-[[4-[(4-chlorobenzoyl)amino]phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=CC(Cl)=CC=3)=CC=2)=N1 LACBHKONDFDLLO-UHFFFAOYSA-N 0.000 claims 1
- YTMBTJPYTXLXLT-UHFFFAOYSA-N 2-[2-[[4-[(4-chlorobenzoyl)amino]phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=CN=C1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 YTMBTJPYTXLXLT-UHFFFAOYSA-N 0.000 claims 1
- PTVJXKKBDDFIEH-UHFFFAOYSA-N 2-[2-[[4-[(4-fluorobenzoyl)amino]phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=CN=C1CC(C=C1)=CC=C1NC(=O)C1=CC=C(F)C=C1 PTVJXKKBDDFIEH-UHFFFAOYSA-N 0.000 claims 1
- VIADXYASLLIBBI-NTEUORMPSA-N 2-[2-[[4-[[(e)-3-(4-chlorophenyl)prop-2-enoyl]amino]phenyl]methyl]-4,6-bis(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)\C=C\C=3C=CC(Cl)=CC=3)=CC=2)=N1 VIADXYASLLIBBI-NTEUORMPSA-N 0.000 claims 1
- FLVDJNIFQHPSAB-KPKJPENVSA-N 2-[2-[[4-[[(e)-3-(4-chlorophenyl)prop-2-enoyl]amino]phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)\C=C\C=3C=CC(Cl)=CC=3)=CC=2)=N1 FLVDJNIFQHPSAB-KPKJPENVSA-N 0.000 claims 1
- NRDKCQHKFLCXRT-UHFFFAOYSA-N 2-[2-[[4-[[benzyl(methyl)carbamoyl]amino]phenyl]methyl]-4-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)N(C)CC=3C=CC=CC=3)=CC=2)=N1 NRDKCQHKFLCXRT-UHFFFAOYSA-N 0.000 claims 1
- HRFIBVDUAZPDBR-UHFFFAOYSA-N 2-[4,6-bis(dimethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 HRFIBVDUAZPDBR-UHFFFAOYSA-N 0.000 claims 1
- JBCJIXHGOBOQOI-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[1-[4-(quinoline-2-carbonylamino)phenyl]ethyl]pyrimidin-5-yl]acetic acid Chemical compound C=1C=C(NC(=O)C=2N=C3C=CC=CC3=CC=2)C=CC=1C(C)C1=NC=C(CC(O)=O)C(N(C)C)=N1 JBCJIXHGOBOQOI-UHFFFAOYSA-N 0.000 claims 1
- HFENOWNHMIFNFE-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[1-[4-[(4-fluorobenzoyl)amino]phenyl]ethyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C=C(CC(O)=O)C(N(C)C)=NC=1C(C)C(C=C1)=CC=C1NC(=O)C1=CC=C(F)C=C1 HFENOWNHMIFNFE-UHFFFAOYSA-N 0.000 claims 1
- WXBFZIGGWGVNCY-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]-6-propan-2-ylpyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(C(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 WXBFZIGGWGVNCY-UHFFFAOYSA-N 0.000 claims 1
- VZQIUAMJIMFSOW-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC=1C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC=1N1CCCC1 VZQIUAMJIMFSOW-UHFFFAOYSA-N 0.000 claims 1
- XSGQONMWVRQSTD-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 XSGQONMWVRQSTD-UHFFFAOYSA-N 0.000 claims 1
- SETQVYMZHIVBRU-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-(phenylmethoxycarbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)OCC=3C=CC=CC=3)=CC=2)=N1 SETQVYMZHIVBRU-UHFFFAOYSA-N 0.000 claims 1
- WZQHWHBFSVGSTJ-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-(quinoline-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3N=C4C=CC=CC4=CC=3)=CC=2)=N1 WZQHWHBFSVGSTJ-UHFFFAOYSA-N 0.000 claims 1
- ZSKOFFLYTKCEIM-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(3-methoxybenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(CC=3N=C(C(CC(O)=O)=CN=3)N(C)C)=CC=2)=C1 ZSKOFFLYTKCEIM-UHFFFAOYSA-N 0.000 claims 1
- PBUBGDUPQPHGCQ-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(3-phenoxybenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C(C=1)=CC=CC=1OC1=CC=CC=C1 PBUBGDUPQPHGCQ-UHFFFAOYSA-N 0.000 claims 1
- ZQDSPCGDTTZJGO-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(4-fluorobenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C1=CC=C(F)C=C1 ZQDSPCGDTTZJGO-UHFFFAOYSA-N 0.000 claims 1
- JQMMXIYSINFBCU-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(4-nitrophenyl)methoxycarbonylamino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)OCC=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=N1 JQMMXIYSINFBCU-UHFFFAOYSA-N 0.000 claims 1
- RQZCDOIOWMSAAL-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(4-phenoxybenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 RQZCDOIOWMSAAL-UHFFFAOYSA-N 0.000 claims 1
- QAAHQJRWEYVWSL-UHFFFAOYSA-N 2-[4-(dimethylamino)-2-[[4-[(4-phenylbenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 QAAHQJRWEYVWSL-UHFFFAOYSA-N 0.000 claims 1
- JXZKZHYRSWFZLW-NTCAYCPXSA-N 2-[4-(dimethylamino)-2-[[4-[[(e)-3-phenylprop-2-enoyl]amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)\C=C\C1=CC=CC=C1 JXZKZHYRSWFZLW-NTCAYCPXSA-N 0.000 claims 1
- QCPVMOCGIQWSRP-UHFFFAOYSA-N 2-[4-(dimethylamino)-6-(methoxymethyl)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(COC)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 QCPVMOCGIQWSRP-UHFFFAOYSA-N 0.000 claims 1
- SBKQRLWONFKCFV-UHFFFAOYSA-N 2-[4-(dimethylamino)-6-ethyl-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound CN(C)C1=C(CC(O)=O)C(CC)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 SBKQRLWONFKCFV-UHFFFAOYSA-N 0.000 claims 1
- OMDIJQIRAXUPFB-UHFFFAOYSA-N 2-[4-(dimethylamino)-6-methyl-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 OMDIJQIRAXUPFB-UHFFFAOYSA-N 0.000 claims 1
- OGZNYVIPIIDZLY-UHFFFAOYSA-N 2-[4-(dimethylamino)-6-morpholin-4-yl-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC=1C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC=1N1CCOCC1 OGZNYVIPIIDZLY-UHFFFAOYSA-N 0.000 claims 1
- DINJPARSGWZJLN-JLHYYAGUSA-N 2-[4-(dimethylamino)-6-morpholin-4-yl-2-[[4-[[(e)-3-phenylprop-2-enoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(N2CCOCC2)=C(CC(O)=O)C(N(C)C)=NC=1CC(C=C1)=CC=C1NC(=O)\C=C\C1=CC=CC=C1 DINJPARSGWZJLN-JLHYYAGUSA-N 0.000 claims 1
- QYVRVZPJYVZRJY-UHFFFAOYSA-N 2-[4-(dimethylamino)-6-pyrrolidin-1-yl-2-[[4-(quinoline-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC=1C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3N=C4C=CC=CC4=CC=3)=CC=2)=NC=1N1CCCC1 QYVRVZPJYVZRJY-UHFFFAOYSA-N 0.000 claims 1
- FZZZSCVAJSHOTP-UHFFFAOYSA-N 2-[4-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 FZZZSCVAJSHOTP-UHFFFAOYSA-N 0.000 claims 1
- BUVUXCNBRMWLTA-DTQAZKPQSA-N 2-[4-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-[[(e)-3-phenylprop-2-enoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)\C=C\C=3C=CC=CC=3)=CC=2)=NC=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 BUVUXCNBRMWLTA-DTQAZKPQSA-N 0.000 claims 1
- HQHRZNWIJUFQFR-UHFFFAOYSA-N 2-[4-chloro-2-[[3-[(2,3-dichlorobenzoyl)amino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=C(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C=CC=2)=N1 HQHRZNWIJUFQFR-UHFFFAOYSA-N 0.000 claims 1
- WEUSPEBVRKDRLM-UHFFFAOYSA-N 2-[4-chloro-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]-6-piperidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC1=C(Cl)N=C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)N=C1N1CCCCC1 WEUSPEBVRKDRLM-UHFFFAOYSA-N 0.000 claims 1
- UAPLHVKACQBFRY-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(2,5-dichlorobenzoyl)amino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C(=CC=C(Cl)C=3)Cl)=CC=2)=N1 UAPLHVKACQBFRY-UHFFFAOYSA-N 0.000 claims 1
- JCPPYXISAHHCPF-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)=CC=2)=N1 JCPPYXISAHHCPF-UHFFFAOYSA-N 0.000 claims 1
- YGFDDDQXTSQSQN-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=C(Cl)N=C1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C(Cl)=C1 YGFDDDQXTSQSQN-UHFFFAOYSA-N 0.000 claims 1
- PICHTDWCXIURKN-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(3,4-difluorobenzoyl)amino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C(F)C(F)=CC=3)=CC=2)=N1 PICHTDWCXIURKN-UHFFFAOYSA-N 0.000 claims 1
- SFKVETIQAWQTMS-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(3,5-dichlorobenzoyl)amino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C(Cl)C=C(Cl)C=3)=CC=2)=N1 SFKVETIQAWQTMS-UHFFFAOYSA-N 0.000 claims 1
- QKSKYWATPYQNRY-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(3-chloro-4-methoxybenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=C(Cl)C(OC)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N2CCCC2)=N1 QKSKYWATPYQNRY-UHFFFAOYSA-N 0.000 claims 1
- LAPHHRQYUAOFGX-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-chlorobenzoyl)-methylamino]phenyl]methyl]-6-(dimethylamino)pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(=CC=2)N(C)C(=O)C=2C=CC(Cl)=CC=2)=N1 LAPHHRQYUAOFGX-UHFFFAOYSA-N 0.000 claims 1
- WXARHGJSLJJRPG-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-chlorobenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=C(Cl)N=C1CC(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 WXARHGJSLJJRPG-UHFFFAOYSA-N 0.000 claims 1
- SLPMFCFFPOSDJT-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-methoxy-3,5-dimethylbenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=C(C)C(OC)=C(C)C=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N2CCCC2)=N1 SLPMFCFFPOSDJT-UHFFFAOYSA-N 0.000 claims 1
- MADNSGWBZDSODE-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-methoxy-3-nitrobenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N2CCCC2)=N1 MADNSGWBZDSODE-UHFFFAOYSA-N 0.000 claims 1
- RGPFGWBVFSTDOG-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-phenoxybenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound N1=C(N2CCCC2)C(CC(=O)O)=C(Cl)N=C1CC(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 RGPFGWBVFSTDOG-UHFFFAOYSA-N 0.000 claims 1
- NCBINUVTUKRPQC-UHFFFAOYSA-N 2-[4-chloro-2-[[4-[(4-propan-2-yloxybenzoyl)amino]phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N2CCCC2)=N1 NCBINUVTUKRPQC-UHFFFAOYSA-N 0.000 claims 1
- FEQHBGJZYPBKBZ-UHFFFAOYSA-N 2-[4-chloro-6-(2,5-dihydropyrrol-1-yl)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC1=C(Cl)N=C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)N=C1N1CC=CC1 FEQHBGJZYPBKBZ-UHFFFAOYSA-N 0.000 claims 1
- JDIZIXSBVMDTGP-UHFFFAOYSA-N 2-[4-chloro-6-(3-hydroxypyrrolidin-1-yl)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1C(O)CCN1C1=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C1CC(O)=O JDIZIXSBVMDTGP-UHFFFAOYSA-N 0.000 claims 1
- VHSVZJXHYNEFJG-UHFFFAOYSA-N 2-[4-chloro-6-(diethylamino)-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(CC)CC)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 VHSVZJXHYNEFJG-UHFFFAOYSA-N 0.000 claims 1
- RXKPEAXSSMKIKT-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[3-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=C(NC(=O)C=3C=C4C=CC=CC4=CC=3)C=CC=2)=N1 RXKPEAXSSMKIKT-UHFFFAOYSA-N 0.000 claims 1
- LCJAFWINFNKCGV-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[3-[(4-sulfamoylbenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=C(NC(=O)C=3C=CC(=CC=3)S(N)(=O)=O)C=CC=2)=N1 LCJAFWINFNKCGV-UHFFFAOYSA-N 0.000 claims 1
- BFMGMGYWQIAUDB-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-(1h-indole-6-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4NC=CC4=CC=3)=CC=2)=N1 BFMGMGYWQIAUDB-UHFFFAOYSA-N 0.000 claims 1
- YUCAAEGJPQENEU-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-(quinoline-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)C)=NC(CC=2C=CC(NC(=O)C=3N=C4C=CC=CC4=CC=3)=CC=2)=N1 YUCAAEGJPQENEU-UHFFFAOYSA-N 0.000 claims 1
- XOYVUOXXCXNZOO-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-[(3-methoxybenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(CC=3N=C(C(CC(O)=O)=C(Cl)N=3)N(C)C)=CC=2)=C1 XOYVUOXXCXNZOO-UHFFFAOYSA-N 0.000 claims 1
- SCBZDUVBOFIDSN-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-[(4-methoxybenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N(C)C)=N1 SCBZDUVBOFIDSN-UHFFFAOYSA-N 0.000 claims 1
- SRIRZKGHEYTTGC-UHFFFAOYSA-N 2-[4-chloro-6-(dimethylamino)-2-[[4-[[4-(dimethylamino)benzoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=CC(N(C)C)=CC=C1C(=O)NC(C=C1)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N(C)C)=N1 SRIRZKGHEYTTGC-UHFFFAOYSA-N 0.000 claims 1
- AQKMGBOJZABCHV-UHFFFAOYSA-N 2-[4-chloro-6-[2-hydroxyethyl(methyl)amino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(CCO)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 AQKMGBOJZABCHV-UHFFFAOYSA-N 0.000 claims 1
- BKKCKMSIZYLPNF-UHFFFAOYSA-N 2-[4-chloro-6-[2-methoxyethyl(methyl)amino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)CCOC)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 BKKCKMSIZYLPNF-UHFFFAOYSA-N 0.000 claims 1
- CNQWNLPWQQBGDN-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(1h-indole-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3NC4=CC=CC=C4C=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 CNQWNLPWQQBGDN-UHFFFAOYSA-N 0.000 claims 1
- PQDSVZKQRJUFGG-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(furan-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3OC=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 PQDSVZKQRJUFGG-UHFFFAOYSA-N 0.000 claims 1
- REOQOVRNRZHSGC-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(hexanoylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound C1=CC(NC(=O)CCCCC)=CC=C1CC1=NC(Cl)=C(CC(O)=O)C(N(C)CC(=O)NC2CCCC2)=N1 REOQOVRNRZHSGC-UHFFFAOYSA-N 0.000 claims 1
- BSDWMUIIHHCWPD-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(naphthalen-2-ylcarbamoylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)NC=3C=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 BSDWMUIIHHCWPD-UHFFFAOYSA-N 0.000 claims 1
- VFOHQDALEDWCOB-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(naphthalene-1-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C4=CC=CC=C4C=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 VFOHQDALEDWCOB-UHFFFAOYSA-N 0.000 claims 1
- ZSSFQQJWTVRIMO-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 ZSSFQQJWTVRIMO-UHFFFAOYSA-N 0.000 claims 1
- SKCKIMHDWORJOM-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-[(3,4-dichlorobenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 SKCKIMHDWORJOM-UHFFFAOYSA-N 0.000 claims 1
- QQMRDTNQAFALAD-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-[(4-methylbenzoyl)amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=CC(C)=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 QQMRDTNQAFALAD-UHFFFAOYSA-N 0.000 claims 1
- NLWYDXUIACZZHR-DTQAZKPQSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-[[(e)-3-phenylprop-2-enoyl]amino]phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)\C=C\C=3C=CC=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 NLWYDXUIACZZHR-DTQAZKPQSA-N 0.000 claims 1
- UEPMTNBUHWLMBD-UHFFFAOYSA-N 2-[4-chloro-6-[cyclohexyl(methyl)amino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)C1CCCCC1 UEPMTNBUHWLMBD-UHFFFAOYSA-N 0.000 claims 1
- FPCNWYQPLLQDDY-UHFFFAOYSA-N 2-[4-chloro-6-[methyl-[2-oxo-2-(propan-2-ylamino)ethyl]amino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound ClC1=C(CC(O)=O)C(N(C)CC(=O)NC(C)C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=N1 FPCNWYQPLLQDDY-UHFFFAOYSA-N 0.000 claims 1
- NNTXSGFBNMXPTD-UHFFFAOYSA-N 2-[4-methyl-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]-6-pyrrolidin-1-ylpyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC=1C(C)=NC(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC=1N1CCCC1 NNTXSGFBNMXPTD-UHFFFAOYSA-N 0.000 claims 1
- WCXQRECUUAFJSX-UHFFFAOYSA-N 2-[4-pyrrolidin-1-yl-2-[[4-(quinoline-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound OC(=O)CC1=CN=C(CC=2C=CC(NC(=O)C=3N=C4C=CC=CC4=CC=3)=CC=2)N=C1N1CCCC1 WCXQRECUUAFJSX-UHFFFAOYSA-N 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000002391 4-chlorocinnamoyl group Chemical group 0.000 claims 1
- 229940124003 CRTH2 antagonist Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003705 anilinocarbonyl group Chemical group O=C([*])N([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- QYADAAGHLXETIS-UHFFFAOYSA-M sodium;2-[2-[[4-(3-methylbutanoylamino)phenyl]methyl]-4-pyrrolidin-1-ylpyrimidin-5-yl]acetate Chemical compound [Na+].C1=CC(NC(=O)CC(C)C)=CC=C1CC1=NC=C(CC([O-])=O)C(N2CCCC2)=N1 QYADAAGHLXETIS-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 description 12
- 210000003979 eosinophil Anatomy 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 210000003651 basophil Anatomy 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 102000011652 Formyl peptide receptors Human genes 0.000 description 2
- 108010076288 Formyl peptide receptors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- GUFQPWJZEYKENI-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclohexylamino)-2-oxoethyl]-methylamino]-2-[[4-(naphthalene-2-carbonylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCCC1 GUFQPWJZEYKENI-UHFFFAOYSA-N 0.000 description 1
- AZOYPRLBVNQPKE-UHFFFAOYSA-N 2-[4-chloro-6-[[2-(cyclopentylamino)-2-oxoethyl]-methylamino]-2-[[4-(3-phenylpropanoylamino)phenyl]methyl]pyrimidin-5-yl]acetic acid Chemical compound N=1C(CC=2C=CC(NC(=O)CCC=3C=CC=CC=3)=CC=2)=NC(Cl)=C(CC(O)=O)C=1N(C)CC(=O)NC1CCCC1 AZOYPRLBVNQPKE-UHFFFAOYSA-N 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03009384A EP1471057B1 (en) | 2003-04-25 | 2003-04-25 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200508722B true ZA200508722B (en) | 2006-12-27 |
Family
ID=32946880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200508722A ZA200508722B (en) | 2003-04-25 | 2004-04-14 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7812160B2 (https=) |
| EP (2) | EP1471057B1 (https=) |
| JP (2) | JP4671955B2 (https=) |
| KR (1) | KR101110491B1 (https=) |
| CN (2) | CN1809539B (https=) |
| AR (1) | AR043885A1 (https=) |
| AT (2) | ATE316077T1 (https=) |
| AU (1) | AU2004233966B2 (https=) |
| BR (1) | BRPI0409733A (https=) |
| CA (1) | CA2523439C (https=) |
| CL (1) | CL43596B (https=) |
| CY (1) | CY1111295T1 (https=) |
| DE (2) | DE60303238T2 (https=) |
| DK (2) | DK1471057T3 (https=) |
| DO (1) | DOP2004000875A (https=) |
| ES (2) | ES2257616T3 (https=) |
| GT (1) | GT200400079A (https=) |
| HN (1) | HN2004000129A (https=) |
| IL (1) | IL171566A (https=) |
| MX (1) | MXPA05011399A (https=) |
| MY (1) | MY147984A (https=) |
| NO (1) | NO20055588L (https=) |
| NZ (1) | NZ543693A (https=) |
| PE (1) | PE20050143A1 (https=) |
| PL (1) | PL1633726T3 (https=) |
| PT (2) | PT1471057E (https=) |
| RU (1) | RU2361865C2 (https=) |
| SI (1) | SI1633726T1 (https=) |
| TW (1) | TWI353980B (https=) |
| UY (1) | UY28286A1 (https=) |
| WO (1) | WO2004096777A1 (https=) |
| ZA (1) | ZA200508722B (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| DE60303238T2 (de) | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| SG10201404273QA (en) * | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| CA2551778C (en) | 2004-01-31 | 2013-10-22 | Actimis Pharmaceuticals, Inc. | Imidazo[1,2-c]pyrimidinylacetic acid derivatives |
| AU2005229356B2 (en) | 2004-03-11 | 2011-06-09 | Idorsia Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| JP5208510B2 (ja) | 2004-11-23 | 2013-06-12 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体 |
| US8796280B2 (en) | 2005-04-21 | 2014-08-05 | Merck Serono, S.A. | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors |
| NZ562772A (en) | 2005-05-24 | 2010-01-29 | Serono Lab | Tricyclic spiro derivatives as CRTH2 modulators |
| PE20110118A1 (es) * | 2005-10-04 | 2011-03-08 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| US8148572B2 (en) | 2005-10-06 | 2012-04-03 | Astrazeneca Ab | Compounds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007062677A1 (en) * | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| EA200802415A1 (ru) * | 2006-06-09 | 2009-06-30 | Икос Корпорейшн | Замещенные фенилуксусные кислоты в качестве dp-2-антагонистов |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| CN103172573A (zh) * | 2007-06-21 | 2013-06-26 | 艾克提麦斯医药品有限公司 | Crth2 拮抗剂的微粒 |
| JP6006914B2 (ja) * | 2007-06-21 | 2016-10-12 | アクチミス ファーマシューティカルズ インコーポレーテッド | Ｃｒｔｈ２アンタゴニストのアミン塩 |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| ATE547407T1 (de) * | 2007-09-25 | 2012-03-15 | Actimis Pharmaceuticals Inc | Alkylthiopyrimidine als crth2-antagonisten |
| WO2009042139A1 (en) * | 2007-09-25 | 2009-04-02 | Actimis Pharmaceuticals, Inc. | 2-s-benzyl substituted pyrimidines as crth2 antagonists |
| CN101952244B (zh) | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂 |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| WO2009145989A2 (en) | 2008-04-02 | 2009-12-03 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
| EP2307362A4 (en) | 2008-07-03 | 2012-05-09 | Panmira Pharmaceuticals Llc | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| CA2735722A1 (en) * | 2008-09-02 | 2010-03-11 | Actimis Pharmaceuticals, Inc. | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| CA2747795A1 (en) * | 2008-12-25 | 2010-07-01 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
| JP2012517405A (ja) * | 2009-02-09 | 2012-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器及び胃腸の疾患の治療のための新規医薬組成物 |
| US8273769B2 (en) | 2009-02-12 | 2012-09-25 | Merck Serono Sa | Phenoxy acetic acid derivatives |
| WO2010094643A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| KR20120038544A (ko) | 2009-07-31 | 2012-04-23 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 수용체 길항제의 안과용 약학 조성물 |
| CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
| GB0913636D0 (en) * | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX2012006003A (es) * | 2009-11-24 | 2012-06-19 | Boehringer Ingelheim Int | Procedimiento para preparar un polimorfo de la sal de colina de [4,6-bis(dimetilamino)-2-(4-{[4-(trifluorometil)-benzoil]amino}be ncil)pirimidin-5-ilo]. |
| CA2782085A1 (en) | 2010-01-06 | 2011-07-14 | Panmira Pharmaceuticals, Llc | Dp2 antagonist and uses thereof |
| HRP20150898T1 (hr) | 2010-01-27 | 2015-10-09 | Boehringer Ingelheim International Gmbh | Spojevi pirazola kao antagonisti crth2 |
| US20130096310A1 (en) | 2010-06-23 | 2013-04-18 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
| EP2590944B1 (en) | 2010-07-05 | 2015-09-30 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| JP2013535456A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| EP2598145A1 (en) * | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| RU2560414C2 (ru) | 2010-10-20 | 2015-08-20 | Вэлспар Сорсинг, Инк. | Система покрытия на водной основе с улучшенной адгезией к подложкам с покрытием и подложкам без покрытия, в том числе к коррозийно-стойкой нержавеющей стали |
| JP2013542243A (ja) | 2010-11-15 | 2013-11-21 | カトリーケ ウニヴェルシテイト ルーヴェン | 新規な抗ウイルス性化合物 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US8759386B2 (en) | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| WO2012130633A1 (en) | 2011-03-25 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as crth2 antagonists |
| RS56326B1 (sr) * | 2011-05-16 | 2017-12-29 | Actimis Pharmaceuticals Inc | Postupak za pripremu [4,6-bis-dimetilamino-2-[4-(4-trifluorometilbenzoil-amino)benzil]pirimidin-5-il]sirćetne kiseline |
| EP2790696A1 (en) | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| JP6097765B2 (ja) | 2011-12-21 | 2017-03-15 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| WO2014006585A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| US20140148470A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrimidine compounds for treating hairloss |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| US6326368B1 (en) * | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| BR9712000A (pt) * | 1996-09-06 | 1999-08-24 | Nippon Kayaku Kk | Derivados de acetamida sais dos mesmos composi-Æo farmac-utica inibidores de protease de quimase de desgranula-Æo de mastÄcitos ou de libera-Æo de histamina de mastÄcitos e de ativa-Æo de eosinÄfilo ou de libera-Æo de oxig-nio ativo de eosinÄfilo e processo para produzir os dervados de acetamida |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| AU2001260081B2 (en) * | 2000-05-22 | 2005-07-28 | Leo Pharma A/S | Benzophenones as inhibitors of il-1beta and tnf-alpha |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1413306A1 (en) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
| ZA200505523B (en) | 2002-12-20 | 2006-09-27 | Amgen Inc | Asthma and allergic inflammation modulators |
| DE60303238T2 (de) | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| CN103172573A (zh) | 2007-06-21 | 2013-06-26 | 艾克提麦斯医药品有限公司 | Crth2 拮抗剂的微粒 |
| JP6006914B2 (ja) | 2007-06-21 | 2016-10-12 | アクチミス ファーマシューティカルズ インコーポレーテッド | Ｃｒｔｈ２アンタゴニストのアミン塩 |
-
2003
- 2003-04-25 DE DE60303238T patent/DE60303238T2/de not_active Expired - Lifetime
- 2003-04-25 DK DK03009384T patent/DK1471057T3/da active
- 2003-04-25 ES ES03009384T patent/ES2257616T3/es not_active Expired - Lifetime
- 2003-04-25 AT AT03009384T patent/ATE316077T1/de active
- 2003-04-25 EP EP03009384A patent/EP1471057B1/en not_active Expired - Lifetime
- 2003-04-25 PT PT03009384T patent/PT1471057E/pt unknown
-
2004
- 2004-04-01 DO DO2004000875A patent/DOP2004000875A/es unknown
- 2004-04-14 US US10/554,668 patent/US7812160B2/en not_active Expired - Fee Related
- 2004-04-14 JP JP2006505114A patent/JP4671955B2/ja not_active Expired - Fee Related
- 2004-04-14 CN CN2004800173378A patent/CN1809539B/zh not_active Expired - Fee Related
- 2004-04-14 PL PL04727274T patent/PL1633726T3/pl unknown
- 2004-04-14 RU RU2005136655/04A patent/RU2361865C2/ru not_active IP Right Cessation
- 2004-04-14 AU AU2004233966A patent/AU2004233966B2/en not_active Ceased
- 2004-04-14 DK DK04727274.5T patent/DK1633726T3/da active
- 2004-04-14 PT PT04727274T patent/PT1633726E/pt unknown
- 2004-04-14 EP EP04727274A patent/EP1633726B1/en not_active Expired - Lifetime
- 2004-04-14 WO PCT/EP2004/003910 patent/WO2004096777A1/en not_active Ceased
- 2004-04-14 NZ NZ543693A patent/NZ543693A/en not_active IP Right Cessation
- 2004-04-14 AT AT04727274T patent/ATE494279T1/de active
- 2004-04-14 CN CN2010101716294A patent/CN101914065A/zh active Pending
- 2004-04-14 BR BRPI0409733-5A patent/BRPI0409733A/pt not_active IP Right Cessation
- 2004-04-14 MX MXPA05011399A patent/MXPA05011399A/es active IP Right Grant
- 2004-04-14 DE DE602004030907T patent/DE602004030907D1/de not_active Expired - Lifetime
- 2004-04-14 SI SI200431585T patent/SI1633726T1/sl unknown
- 2004-04-14 ZA ZA200508722A patent/ZA200508722B/en unknown
- 2004-04-14 ES ES04727274T patent/ES2358424T3/es not_active Expired - Lifetime
- 2004-04-14 CA CA2523439A patent/CA2523439C/en not_active Expired - Fee Related
- 2004-04-14 KR KR1020057020304A patent/KR101110491B1/ko not_active Expired - Fee Related
- 2004-04-19 AR ARP040101311A patent/AR043885A1/es not_active Application Discontinuation
- 2004-04-21 GT GT200400079A patent/GT200400079A/es unknown
- 2004-04-21 HN HN2004000129A patent/HN2004000129A/es unknown
- 2004-04-22 MY MYPI20041479A patent/MY147984A/en unknown
- 2004-04-23 PE PE2004000402A patent/PE20050143A1/es not_active Application Discontinuation
- 2004-04-23 CL CL200400874A patent/CL43596B/es active
- 2004-04-23 UY UY28286A patent/UY28286A1/es not_active Application Discontinuation
- 2004-04-23 TW TW093111323A patent/TWI353980B/zh not_active IP Right Cessation
-
2005
- 2005-10-26 IL IL171566A patent/IL171566A/en not_active IP Right Cessation
- 2005-11-25 NO NO20055588A patent/NO20055588L/no not_active Application Discontinuation
-
2010
- 2010-08-25 US US12/868,663 patent/US7960393B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249273A patent/JP5161290B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-03 CY CY20111100113T patent/CY1111295T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200508722B (en) | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | |
| JP2006524645A5 (https=) | ||
| JP4064671B2 (ja) | アデノシン受容体モジュレーター | |
| US7635701B2 (en) | Pyrimidine derivatives and their use as CB2 modulators | |
| ES2361146T3 (es) | Derivados de la piramidina inhibitatoria de vih. | |
| US7919487B2 (en) | Heteroaryl compounds | |
| EP1442024B1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | |
| JP3507917B2 (ja) | Ｈｉｖを阻害するピリミジン誘導体 | |
| US6716851B2 (en) | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof | |
| BG106521A (bg) | Антивирусни състави | |
| RU2006131304A (ru) | Производные имидазо[1,2-c]пиримидинилуксусной кислоты | |
| JP2004517925A5 (https=) | ||
| US6319922B1 (en) | Propanoic acid derivatives | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| EP1351691A1 (en) | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| WO2006034473A2 (en) | Novel pyrimidine compounds, process for their preparation and compositions containing them | |
| JP2013517273A5 (https=) | ||
| CA2663366A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| JP2005517672A5 (https=) | ||
| WO2006125616A2 (en) | Pyrimidine-based cdk inhibitors for treating pain | |
| JP2007537255A (ja) | 抗−サイトカインヘテロ環式化合物 | |
| AU2009208712B2 (en) | Novel heterocycles | |
| US7863446B2 (en) | Heterocycles | |
| US20080261977A1 (en) | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | |
| CN100451004C (zh) | 嘧啶衍生物 |